Sustainability Report 2014-2015 - Roche Latin America

 
Sustainability Report 2014-2015 - Roche Latin America
Roche Latin America

       Sustainability
       Report
       2014-2015
Sustainability Report 2014-2015 - Roche Latin America
Sustainability Report 2014-2015 - Roche Latin America
Coordination, editing, and content verification                      Find out more:
Edelman

Graphic design and layout
2MCINE

Data and photos provided by
Roche Global and Roche country affiliates

Roche Latin America
Produtos Roche Químicos e Farmacêuticos S.A.
Av. Engenheiro Billings, 1.729 – Jaguaré
CEP 05321-900 – São Paulo/SP, Brazil

All Rights Reserved
Partial or total reproduction of this report is prohibited without
the prior authorization of F. Hoffmann-La Roche Ltd                  Our global sustainability website at:
                                                                     http://www.roche.com/responsibility.htm

Support with identification, provision and accuracy of content:

Argentina                                                            Ecuador
Productos Roche S. A. Q. e I.                                        Roche Ecuador S.A.
Rawson 3150, (B1610BAL), Ricardo Rojas, Tigre                        Av. 10 de Agosto N36-239 y Naciones Unidas, Casilla: 1711-06185
Província de Buenos Aires, Argentina                                 Quito, Ecuador

Brazil                                                               Mexico
Produtos Roche Químicos e Farmacêuticos S.A.                         Productos Roche S. A. de C.V.
Av. Engenheiro Billings, 1.729 – Jaguaré                             Cerrada de Bezares No. 9
CEP 05321-900 – São Paulo/SP, Brazil                                 Col. Lomas de Bezares
                                                                     11910, Mexico, D.F.
Central America and the Caribbean
Productos Roche S.A.                                                 Peru
Zona Franca Ultrapark, Edificio 4                                    Roche Perú
La Aurora, Heredia, Costa Rica                                       San Isidro, Dionísio Derteano 144 of. 1301
                                                                     Lima, Peru
Chile
Roche Chile Ltda.                                                    Uruguay
Av. Cerro el Plomo 5630, Piso 12. Las Condes.                        Roche International Ltd
Santiago, Chile                                                      WTC - Torre 4, Piso 5, Luis Bonavita, 1266
                                                                     Montevideo, Uruguay
Colombia
Productos Roche S.A.                                                 Venezuela
Carrera 44 No. 20-21                                                 Produtos Roche S.A.
Bogotá, Colombia                                                     Edificio Roche, Av. Diego Cisneros, Los Ruices
                                                                     Caracas, Venezuela

4             Roche Latin America 2014-2015 Sustainability Report                                                                      Roche Latin America 2014-2015 Sustainability Report   5
Sustainability Report 2014-2015 - Roche Latin America
Welcome to our
                                                          Sustainibility Report
                                                          2014-2015

                                                          Contents

                                                          1. This Report .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 9               8. Colombia .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 97
                                                                                                                                                                                                                                  Roche Colombia at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 98
                                                          2. Global Overview .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                       11      Healthcare in Colombia . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 99
                                                             Roche at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                           11      Roche in Colombia . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 99
                                                             Roche Group Profile. .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              15      Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 101
                                                             Sustainability Strategy .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              15
                                                                                                                                                                                                                               9. Ecuador .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .          109
                                                          3. Latin America .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                   25      Roche Ecuador at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                           110
                                                             Roche Latin America at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                                    26      Healthcare in Ecuador .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                111
                                                             Healthcare in Latin America .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                         29      Roche in Ecuador . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                          111
                                                             Roche in Latin America .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                  31      Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              113
                                                             Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              33
                                                                                                                                                                                                                               10. Mexico .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .       119
                                                          4. Argentina. .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .             45       Roche Mexico at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                        120
                                                             Roche Argentina at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                            46       Healthcare in Mexico. .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                               121
                                                             Healthcare in Argentina .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                    47       Roche in Mexico. .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                        121
                                                             Roche in Argentina .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                             47       Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                             123
                                                             Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              49
                                                                                                                                                                                                                               11. Peru .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   131
                                                          5. Brazil .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .     59       Roche Peru at a Glance . .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                  132
                                                             Roche Brazil at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                   60       Healthcare in Peru .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                         133
                                                             Healthcare in Brazil .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                           61       Roche in Peru .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                  134
                                                             Roche in Brazil .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                    61       Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                             135
                                                             Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              63
                                                                                                                                                                                                                               12. Uruguay .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .         143
                                                          6. Central America and the Caribbean .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                                        73       Roche Uruguay at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                          144
                                                             Roche Central America and the Caribbean at a Glance . .  .  .  .  .  .                                                                                       74       Healthcare in Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                  145
                                                             Healthcare in Central America                                                                                                                                         Roche in Uruguay .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                           145
                                                             and the Caribbean .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                           75       Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                             147
                                                             Roche in Central America and the Caribbean. . . . . . . . . . . . . . .                                                                                      75
                                                             Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              77   13. Venezuela .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .             157
                                                                                                                                                                                                                                   Roche Venezuela at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                           158
                                                          7. Chile .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   85       Healthcare in Venezuela .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                   159
                                                             Roche Chile at a Glance .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                                    86       Roche in Venezuela .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                            159
                                                             Healthcare in Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                                                87       Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                             161
                                                             Roche in Chile .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                     87
                                                             Sustainability Initiatives .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .                              89

6   Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                                                       Roche Latin America 2014-2015 Sustainability Report                                                                                            7
Sustainability Report 2014-2015 - Roche Latin America
This Report

                                                          At Roche, we are dedicated to doing good business that contrib-   Roche’s most recent sustainability report, 2015 Global Report,(1)
                                                          utes to a better world. Everything we do as a company is guided   follows the GRI G4 standards, and its content is guided by an
                                                          by our commitment to scientific rigor, unassailable ethics, and   updated global materiality assessment. The regional office of
                                                          access to medical innovations for all. We value transparency      Roche in Latin America(2) follows the Group’s approach, and
                                                          and ethical management, and public reporting on our activities    our second regional Sustainability Report is informed by the
                                                          and results is an important tool for promoting both. The Group    GRI G4 methodology.
                                                          has been publishing a sustainability report for more than 10
                                                          years and has adopted the guidelines of the Global Reporting      This report covers Roche’s economic, social, and environmental
                                                          Initiative (GRI).                                                 impacts in Latin America for the two-year period from January 1,
                                                                                                                            2014 to December 31, 2015. The content covers the Pharmaceu-
                                                                                                                            ticals Division in the 10 affiliates comprising the regional group:
                                                                                                                            Argentina, Brazil, Central America and the Caribbean, Chile,
                                                                                                                            Colombia, Ecuador, Mexico, Peru, Uruguay, and Venezuela. The
                                                                                                                            data highlighted in this report are based on key performance in-
                                                                                                                            dicators in all of the listed affiliates.

                                                                  We value transparency                                     Roche believes sustainability is an on-going journey of continu-
                                                                                                                            ous improvement. This report reflects a moment in time on that
                                                                  and ethical management,                                   journey, and Roche is committed to strengthening and expanding
                                                                                                                            its sustainability management processes and tools in the future.
                                                                  and public reporting on
                                                                  our activities and results                                (1)
                                                                                                                                  Roche Annual Report 2015: www.roche.com/gb15e.pdf

                                                                  is an important tool for                                  (2)
                                                                                                                                  In this report, “Roche in Latin America” only refers to its Pharmaceuticals Division.

                                                                  promoting both.

8   Roche Latin America 2014-2015 Sustainability Report                                                                                 Roche Latin America 2014-2015 Sustainability Report                               9
Sustainability Report 2014-2015 - Roche Latin America
Global Overview

                                                           Roche at a Glance
                                                           A global leader in innovation                    A sustainable company                              A great workplace
                                                           Roche is the world’s largest biotech-            Roche is committed to business                     Roche is driven by a shared set of
                                                           nology company and a leader in re-               practices that are sustainable, ethi-              values including integrity, the cour-
                                                           search-focused healthcare.                       cal and responsible to create long-                age to reach beyond boundaries
                                                                                                            term value.                                        and a passion for what we do.

                                                           +100
                                                           Countries
                                                                                                     #1
                                                                                                      in biotech
                                                                                                                                             #1
                                                                                                                                          in oncology and
                                                                                                                                                                                  #1
                                                                                                                                                                            in hospital markets
                                                                                                                                        in vitro diagnostics

                                                           48.1
                                                           billion CHF(3) in sales
                                                                                               9.3
                                                                                               billion CHF in
                                                                                                                                                                           91,747
                                                                                                                                                                           Employees
                                                                                               R&D investment                                                              (full-time equivalents)

                                                           29
                                                           Roche medicines on WHO
                                                                                               70
                                                                                               new medical entities in
                                                                                                                                                                           40%
                                                                                                                                                                           Women
                                                           Essential Medicines List            clinical development                                                        in management roles

                                                                                               25,000,000
                                                                                               Patients treated
                                                                                                                                                               +300,000
                                                                                                                                                               Patients in clinical trials
                                                                                               with one of Roche’s top 25 selling products

                                                           2015 data
                                                           Figures include Pharmaceutical and Diagnostics divisions.

                                                           For further information: www.roche.com
                                                           (3)
                                                                 Swiss francs

10   Roche Latin America 2014-2015 Sustainability Report                                                                                     Roche Latin America 2014-2015 Sustainability Report       11
Sustainability Report 2014-2015 - Roche Latin America
Who we are
                                                           Innovation: it’s in our DNA. At Roche we have always worked across       As the world’s largest biotech company, we develop breakthrough
                                                           disciplines and geographies to drive scientific discovery and redefine   medicines, improving the standard of care across oncology, im-
                                                           what is possible to improve patients’ lives.                             munology, infectious diseases, ophthalmology and neuroscience.
                                                                                                                                    We are also the world leader in the in vitro diagnostics business.
                                                           We work towards understanding how diseases differ down to the            This track record allows us to build lasting and meaningful part-
                                                           molecular level in order to develop new tests and medicines that         nerships across the world with research academia and public
                                                           prevent, diagnose and treat diseases that matter and bring them to       healthcare institutions.
                                                           the patients who need them. With our combined strengths in diag-
                                                           nostics and pharmaceuticals, our personalised healthcare strategy        We remain dedicated to the highest standards of quality, safety and
                                                           aims to fit the right treatment to the right patient.                    integrity. Our legacy is based on respect for the individual, as well
                                                                                                                                    as the communities and the world we live in.

                                                           Our values
                                                           Integrity starts with me.                                                Discovery starts with passion.
                                                           We are consistently open, honest and genuine.                            We use our drive and commitment to energise, engage and in-
                                                                                                                                    spire others.
                                                           Just as we expect it from ourselves and our colleagues, society
                                                           expects that we live by high standards of integrity. Integrity starts    Above all, our passion is to improve patients’ lives, and it is this
                                                           with being honest with oneself and understanding one’s own               passion that fuels our determination and enables us to persevere,
                                                           strengths and weaknesses. It is also about interacting with others       often over many years. Passion can express itself in highly visible
                                                           in an open, genuine way. That is a must for building a strong re-        ways – such as an enthusiastic speech or a persuasive presentation.
                                                           lationship of trust with anyone, whether inside or outside Roche.        It can also be low key – such as persistently repeating an experi-
                                                           We must act ethically and honestly at all times.                         ment over and over again to determine whether an unexpected
                                                                                                                                    result was just an error or possibly an important new discovery.

                                                                                                                                    Success starts with courage.
                                                                                                                                    We are entrepreneurial, taking risks, experimenting and reaching
                                                                                                                                    beyond boundaries.

                                                                                                                                    Our business and strategy takes us often into uncharted territory.
                                                                                                                                    This also means that we must have the courage to take appropri-
                                                                       Above all, our passion                                       ate risks in order to succeed. This means we need to think like
                                                                                                                                    entrepreneurs and be prepared to try new ways of doing things
                                                                       is to improve patients’                                      even if we are convinced that the traditional ways are right. We
                                                                                                                                    may not always feel comfortable about taking a minority view or
                                                                       lives, and it is this                                        expressing criticism. Yet if we don’t speak up, we run the risk of
                                                                                                                                    not tackling necessary changes, whether out of complacency or
                                                                       passion that fuels our                                       an ill-conceived desire for harmony. Being courageous will en-
                                                                                                                                    sure we can remain successful and stay ahead in the long run.
                                                                       determination and
                                                                       enables us to persevere,
                                                                       often over many years.

12   Roche Latin America 2014-2015 Sustainability Report                                                                                  Roche Latin America 2014-2015 Sustainability Report         13
Sustainability Report 2014-2015 - Roche Latin America
Roche Group Profile
                                                           Roche is a global healthcare pioneer advancing science for human-     To date the Roche Group has helped to improve peoples’ health and
                                                           ity. We are committed to bringing these advances to everyone who      quality of life in more than 150 countries all over the world. As a
                                                           needs them, no matter where they live. And this is our promise: to    world leader in research on healthcare products, the company op-
                                                           care about this generation, as well as the ones to come.              erates exclusively in the fields of pharmaceuticals and diagnostics.
                                                                                                                                 The founding families continue to hold the majority stake in the
                                                           Founding Roche in 1896, more than 100 years ago in Switzerland,       company. This stability allows for a tradition of sustainable think-
                                                           our company’s founder, Fritz Hoffmann, turned a pioneering idea       ing, allowing us to learn from setbacks and pass down lasting value
                                                           into reality: that a partnership between business and science can     for patients and society.
                                                           improve peoples’ lives. Expanding globally, our founders tackled
                                                           obstacles, worked across disciplines and cultures and embraced
                                                           risks. This is still how we transform lives, provide cures, comfort
                                                           and hope, to make a difference in the health of millions.

                                                           Sustainability Strategy
                                                           Innovation for Patients – Access to Healthcare
                                                           The Sustainable Development Goals adopted by the Member               In addition, the Roche Group invests heavily in cutting edge
                                                           States of the United Nations in September 2015 include the pro-       research and development (R&D) as part of its commitment to
                                                           motion of ‘good health and well-being.’ As a global healthcare        innovation for patients. Core R&D investments in 2015 totalled
                                                           company, Roche has the opportunity to actively commit and             9.3 billion CHF, or 19.4% of sales with pharmaceuticals repre-
                                                           contribute to achieving this important societal goal. In this vein,   senting a large portion of this corporate commitment.
                                                           Roche has developed five primary pillars that focus on patients
                                                           and improved access to healthcare: Delivering Innovation, In-         External innovation is also crucial to Roche’s strategy of bringing
                                                           creasing Disease Awareness, Strengthening Healthcare Infra-           critical treatments to patients in areas of unmet medical need. We
                                                           structure, Improving Affordability and Supporting Local Patient       currently manage over 200 partnerships worldwide. Our teams
                                                           Organisations.                                                        of experts work closely with internal R&D groups to gauge needs
                                                                                                                                 and gaps. At the same time, they track emerging companies on
                                                                                                                                 academic advances and on other collaborative opportunities,
                                                           Delivering Innovation                                                 screening thousands of potential partners a year before selecting
                                                                                                                                 those that will truly help Roche advance drug discovery and de-
                                                           Roche’s most powerful contribution in this area lies in develop-      velopment in an impactful way.
                                                           ing tests and medicines to meet some of the most urgent medical
                                                           needs worldwide. It is here that we explore ideas, face setbacks
                                                           and relentlessly pursue new approaches to make true advances          Increasing Disease Awareness
                                                           against disease. Our employees remain dedicated to transforming
                                                           science into breakthrough medicines and diagnostics to improve        Improving access to medicines and diagnostics is vital, but still
                                                           the life of each patient in the best way possible.                    not enough to improve global healthcare. A holistic approach of
                                                                                                                                 health education and awareness is also critically important to a
                                                           In pharmaceuticals, Roche is a global leader in oncology, tack-       patient’s long-term outcome. As such, we support local commu-
                                                           ling melanoma, breast, ovarian, cervical and lung cancer, diffi-      nity partners to run screening, awareness and counselling pro-
                                                           cult-to-treat indolent non-Hodgkin lymphoma and many others.          grammes, and help empower people worldwide with the knowl-
                                                           Roche has made important contributions to significantly lower-        edge to safeguard and manage their own health.
                                                           ing cancer mortality rates globally over the past 20 years. In 18
                                                           years, Roche has developed 11 cancer treatments with proven           Through our collaborative efforts with patient groups, hospitals
                                                           survival benefit to patients.                                         and health organisations around the world, we help increase
                                                                                                                                 awareness of diseases such as cancer, rheumatoid arthritis, hep-
                                                           Beyond oncology, Roche is forging innovative treatments in im-        atitis, osteoporosis and diabetes. We also conduct screening pro-
                                                           munology, particularly multiple sclerosis (MS). MS affects ap-        grammes for the early detection of these diseases and publish
                                                           proximately 2.3 million people worldwide; thus, effective treat-      information on newsletters, magazines and other publications
                                                           ment and diagnosis can have impact at scale, improving quality        aimed at helping people make healthy choices and changing be-
                                                           of life for those around the world.                                   haviours to prevent disease.

14   Roche Latin America 2014-2015 Sustainability Report                                                                               Roche Latin America 2014-2015 Sustainability Report        15
Sustainability Report 2014-2015 - Roche Latin America
Innovation for Patients – Access to Healthcare (cont.)

Additional information is also developed specifically for patients,   We believe that all players are required — public authorities,         In a complex global market, we understand that the value of our      Supporting Patient Organisations
families and caregivers who operate counselling services to help      non-governmental stakeholders, patient organisations, local            products, the ability of healthcare systems and individuals to pay
them understand diseases and the proper use of our products.          communities, the healthcare industry and others — to work              for them varies greatly across different regions. To address this    Roche takes patient engagement very seriously and endeavours
They can also find details on the latest information about tests      closely together to improve health and well-being. As a global         issue, we are exploring new pricing models that are tailored to      to support patient organisations’ objectives wherever possible.
and treatment options on a variety of websites that Roche has         healthcare company, Roche plays a key role and shares a respon-        the dynamics of each healthcare system, rather than a uniform        We believe that together, we can spark meaningful change for
helped develop.                                                       sibility to tackle the challenges of improving health outcomes.        pricing structure.                                                   the future of human health. Today our interactions with patient
                                                                      That’s why we are committed to working with partners at the local                                                                           groups are multifaceted and range from funding organisations
                                                                      level to overcome barriers and improve access to tests and medi-       Through this unique approach, we hope to find solutions that         and building capacity to organising meetings and supporting ad-
Strengthening Healthcare Infra­structure                              cines for all patients.                                                allow us to continue to invest in the research and development       vocacy. The International Experience Exchange for Patient Or-
                                                                                                                                             of products that can transform patients’ lives, while balancing      ganisation (IEEPO), Roche’s largest global patient organisation
Roche believes a multi-stakeholder approach to access and infra-                                                                             the needs of our stakeholders and our commitment to improv-          meeting, was held in Munich in 2015 and focused on the vital
structure is key to getting innovation to the patients who need       Improving Affordability                                                ing access.                                                          role of patient organisations. A record total of 189 delegates from
treatment most. Many Roche-developed products can make                                                                                                                                                            41 countries attended IEEPO 2015, and agreed that the potential
healthcare delivery more efficient by improving the mode of ad-       When a new product is brought to market, we work closely with                                                                               role patients can play in research, clinical trial design and recruit-
ministration, or reducing the time patients spend in the hospital.    governments, insurers and other healthcare providers to deter-                                                                              ment, HTA and other aspects of drug development and access,
In addition, advances in science have led to personalised health-     mine its value. This enables us to demonstrate the value of the                                                                             could and should increase significantly.
care that focuses on providing the right treatment for the right      product to patients, their families, healthcare professionals, pay-               R&D investments in
patient. Unlike previous one-size-fits-all methods, personalised      ers and society in general, in order to gain appropriate reimburse-                                                                         We believe in delivering medical solutions urgently, even as we
healthcare recognises that each patient is unique, and by using       ment. We consider numerous factors when determining value,                        2015 totalled 9.3 billion                                 develop innovations for the future. That’s why we are committed
specific diagnostic tests, doctors can now predict how well a pa-     including: the effectiveness of our medicine or diagnostic; other                                                                           to working with partners at the local, regional and global level to
tient responds to treatment for certain diseases or conditions.       medicines or diagnostics used to treat or test the same disease; fu-              CHF, or 19.4% of sales.                                   overcome barriers and improve access to tests and medicines for
These tests also enable physicians to determine the best dosage       ture investment needed to discover new medicines and diagnos-                                                                               all patients.
and duration of treatment.                                            tics; how to ensure that our products get to the people who need
                                                                      them; and the affordability of our product to healthcare systems
                                                                      and individuals.

16         Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                          Roche Latin America 2014-2015 Sustainability Report          17
Sustainability Report 2014-2015 - Roche Latin America
Great Workplace for Employees                                                                                                             Responsible and Compliant Partners
As a science and innovation-driven company, Roche’s most im-         Roche is committed to increasing the representation of key lead-     Compliance is our license to operate and serves as a foundation to   All Roche employees are expected to follow the integrity guide-
portant global asset is our people. We are committed to provid-      ers with established and developing regional experience and          build and maintain trust with our stakeholders. Stakeholder en-      lines outlined in the Roche Group Code of Conduct. In addition
ing the best possible working environment so they can thrive.        providing opportunities for our employees to work in different       gagement is a key pillar of Roche’s comprehensive sustainability     to employees, Roche’s suppliers and service providers are ex-
Globally, we are focused on expanding diversity and inclusion,       environments. We are also committed to increasing the represen-      management process. This allows us to identify and prioritise ma-    pected to adhere to similar standards. Our Roche Supplier Code
providing leadership opportunities for employees and providing       tation of women in key leadership positions. In 2015 we made         terial issues, like at our yearly Sustainability Forum, where more   of Conduct is included in contracts and we offer an e-Learning
a healthy, productive work environment that cares for employees.     progress on this goal, with women now accounting for at least        than 80 internal stakeholders and external experts discuss inno-     programme to help our suppliers and service providers increase
                                                                     23% of leaders in key leadership positions and for 40% of man-       vations in the supply chain, how to improve access to healthcare     their knowledge and understanding of Roche’s expectations and
Our five-year goals for people management globally include:          agement overall.                                                     and elevate sustainability reporting at the partner level, and how   of industry standards. Roche also maintains a stringent process to
• A 30% increase in the representation of women in key leader-                                                                            to enhance employee engagement.                                      qualify and audit current and new suppliers and service provid-
  ship roles                                                         Roche also offers a variety of work-life balance and wellness pro-                                                                        ers. In 2015 we conducted more than 1,000 audits of global and
• A 30% increase in the representation of people with estab-         grammes to employees including opportunities to work remotely,                                                                            local suppliers and service providers.
  lished and developing region experience                            allowances for family leave, health and wellness education, bene-
• A top quartile ranking in overall employee engagement score,       fits and flexible work schedules.                                                                                                         Ensuring patient safety and the effectiveness of our medicinal
  measured by the Global Employee Opinion Survey (GEOS)                                                                                                                                                        products is our top priority. We collaborate with regulatory agen-
                                                                     Roche has consistently been recognised as one of the best com-                  In 2015 we conducted                                      cies, monitor reports of adverse events experienced by patients
Diversity and inclusion are vital as the global marketplace is in-   panies to work for. The company has been consistently awarded                                                                             and communicate on our product safety activities.
creasingly connected. Our business is different across our divi-     placement on several ‘Great Place to Work’ lists, including the                 more than 1,000 audits
sions and the world and employees who understand those dif-          Fortune 100 best companies list, Working Mother magazine’s
ferences are critical to our success. An inclusive culture fosters   100 best companies list, and DiversityInc’s 25 most noteworthy                  of global and local
innovation by encouraging different perspectives, ideas and          companies.
thinking styles. In 2015 we defined what diversity and inclusion                                                                                     suppliers and service
means to us and formalised the Diversity & Inclusion Practi-
tioners’ Network to ensure that leaders are aligned in the way we                                                                                    providers.
bring this commitment to life in our day-to-day business.

18         Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                       Roche Latin America 2014-2015 Sustainability Report      19
Supporting Communities                                                   Protecting the Environment
                                                           Roche is committed to global philanthropic activities including          Safety, security, health and environmental protection are import-      We measure our total environmental impact using the eco-bal-
                                                           community involvement, humanitarian projects, science, edu-              ant and enduring issues in a changing world. At Roche we refer to      ance metric developed by the Swiss Federal Office for the Envi-
                                                           cation, art and culture. We seek to support local communities            activities that address these areas as SHE. We believe that protect-   ronment. This metric provides us with a global view of how we
                                                           through long-lasting partnerships. Following natural disasters           ing people and the environment isn’t just a legal or social obliga-    are impacting the Earth’s ecosystems. Our strategic five-year goal
                                                           such as the 2015 Nepal earthquake and flooding in Malawi and             tion, it’s integral to our operations. For that reason, we approach    is to reduce our eco-balance by 10% by 2019.
                                                           Pakistan, Roche works with local partners to provide immedi-             SHE with the same sense of responsibility – and just as method-
                                                           ate support with essential donations of medicines and long-term          ically – as we do issues concerning product quality, productivity
                                                           support to help communities rebuild. Roche has provided finan-           and cost efficiency.
     Roche has provided                                    cial support and donated millions of treatments for relief efforts,
                                                           including medical products to treat and prevent infectious dis-          Prevention is a key element in all our activities. Our corporate
     financial support and                                 eases in the wake of natural disasters.                                  policies and guidelines outline our commitments for ensuring the
                                                                                                                                    safety of people and protecting the environment. We maintain
     donated millions of                                   Roche also has a long-standing philanthropic commitment in               these standards by adhering to laws and regulations, by cooper-                Protecting people and the
                                                           Malawi, Southeast Africa. Since 2003 Roche has supported ed-             ating with authorities and by communicating openly and frankly
     treatments for relief                                 ucation programmes for HIV/AIDS-orphaned children in the                 about our activities.                                                          environment is integral to
                                                           region. Each year employees donate money and time as part of
     efforts.                                              Roche Children’s Walk reaching over 17,000 children in the re-           Research and pharmaceutical and diagnostic manufacturing are                   our operations.
                                                           gion as well as 90 local communities globally over the past 12           dependent on natural resources, which are becoming increasing-
                                                           years of the programme.                                                  ly scarce. At Roche, our goal is to minimise our impact on the en-
                                                                                                                                    vironment and to increase the use of renewable resources whilst
                                                           These are just a few ways we demonstrate our commitment to               continuing to expand our global business. As part of our com-
                                                           the communities where we live, work and operate. Our goal is             mitment toward sustainable development, we proactively seek to
                                                           to establish long-term partnerships by focusing on projects that         employ new, more sustainable technologies and processes.
                                                           add lasting value to society at the global, regional and local levels.

20   Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                         Roche Latin America 2014-2015 Sustainability Report      21
Protecting the Environment (cont.)                                                                                                            External Recognition

As a global player, Roche has the opportunity to reduce its impact     Roche strives to implement the following strategy in its activi-       Roche has been named to the CDP(4) A List, awarded as a CDP
on climate. We have prioritised energy efficiency and renewable        ties — avoid, reduce, reuse, recycle, thermally destroy. We permit     Climate Disclosure Leader, and in 2015 Roche became an Indus-
energy sourcing as two key ways to reduce our climate footprint.       landfilling only as a last resort and, even then, only for inert ma-   try Leader in Dow Jones Sustainability Index for the 7th consecu-
Since 2010 a total of 1,063 energy-saving projects have been com-      terials such as slag or incineration ash. Depending on the avail-      tive year(5). Our efforts were also recognised by Newsweek, which
pleted, yielding a reduction of approximately 127,000 tonnes of        ability of suitable local waste-treatment plants, we may dispose of    ranked Roche as the number 9 greenest company in the world’s                   Industry Leader
CO2 emissions and an estimated cost saving of CHF 27.6 mil-            non-hazardous general waste in authorised landfills. Roche does        500 largest publicly-traded companies (by market capitalisation)               for the 7th consecutive year
lion per year. Roche has also recently set a 10-year goal (2015–       not accept landfilling of chemical waste or other hazardous ma-        also in 2015.                                                                  (According to Dow Jones Sustainability Index)
2025) to reduce energy intensity (gigajoule/employee) within our       terials. In 2015 we set new goals for general and chemical waste
owned facilities and purchased energy consumed by us by 15%.           reduction: reduce general waste per employee by 10% over a five-
By approximately 2050, we expect to reduce energy consumption          year period and reduce landfilling of organic chemicals by 50%
per employee by approximately 50%, compared to 2005 baseline           over a five-year period.
                                                                                                                                              (4)
                                                                                                                                                    CDP is formerly the Carbon Disclosure Project
                                                                                                                                              (5)
                                                                                                                                                    Dow Jones Sustainability Indices: www.sustainability-indices.com/
levels. Additionally, we plan to increase the proportion of sustain-
able energy use to 20% by 2020.                                        Operationally, Roche is compliant with all local and regional laws
                                                                       on environment, health, and safety and as such, we also focus on
For the pharmaceutical industry globally, poor quality water is re-    environmental responsibility, compliance, prevention and reduc-
sulting in higher costs for purification and greater risk of product   tion of occupational accidents and supply chain management as
contamination. The demand for fresh water is increasing and an         part of a broad commitment to corporate responsibility. In Safe-
effective water management is crucial to avoid water scarcity. Our     ty, Health and Environmental protection we employ 651 peo-
aim is to protect water resources by reducing the amount of water      ple worldwide and 491 people in Security. Expert teams at each
consumption, recycling water where possible and purifying water        Roche site identify risks and develop mitigation plans.
to protect water quality. Our 2015–2020 water goal is to reduce
consumption per employee by 10%, weighted according to the
water stress for a respective region.

22         Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                          Roche Latin America 2014-2015 Sustainability Report   23
Watch video here                                                                       Latin America

                                                                                  “Distinguishing health journalism means promoting
                                                                                  quality information around a matter of fundamental
                                                                                  importance for society.”                                  Jaime Abello Banfi
                                                                                                                                            General Director of the Gabriel García Márquez
                                                                                                                                            Foundation for New Ibero-American Journalism (FNPI)

                                                           At FNPI we work to promote excellence in journalism, and to           In this context, journalists play the key educational role of help-
                                                           support the contribution reporters make to the development of         ing generate a better understanding among the general public of
                                                           countries across Latin America and the Caribbean. In this spirit,     complex health issues, raising awareness, and guiding people to-
                                                           since 2013 we have a collaboration project with Roche that con-       wards better self-care for disease prevention. In this way, health
                                                           sists of a health journalism award. In this effort, the FNPI func-    journalists become drivers of value and benefits for society.
                                                           tions as the technical secretariat, handling the entire process to
                                                           ensure its professionalism and independence.                          The main goal of the Roche Award for Health Journalism is to
                                                                                                                                 contribute to communities across Latin America by recognizing
                                                           The issue of health is increasingly important and complex. It is      and promoting good journalistic practices and quality coverage
                                                           no longer just about the traditional doctor-patient relationship, a   of health topics. And at the same time, through workshops and
                                                           merely medical or scientific issue. Today, people are evermore af-    the broadcasting of distinguished works, the award also looks
                                                           fected and concerned by healthcare, as it spreads across political,   to open a space for discussion and knowledge-exchange, among
                                                           social and economic dimensions.                                       journalists and between them, experts and other key stakehold-
                                                                                                                                 ers. Above all, it is about driving attention and encouraging
                                                                                                                                 high-quality information around a matter of critical and increas-
                                                                                                                                 ing importance.

24   Roche Latin America 2014-2015 Sustainability Report                                                                               Roche Latin America 2014-2015 Sustainability Report        25
Roche Latin America                                                  São Paulo, Brazil         1930
at a Glance                                                          Headquarters              Established

                                                                                                         Women in
                 Headcount                                           Women                               Key Positions

                 4,328                                               50.5%                               42.9%
                 2014                                                2014                                2014

                 4,335                                               51.2%                               42.8%
                 2015                                                2015                                2015

                 Turn Over Rate                                      New Hires                           Internal Hires

                 13%                                                 695                                 237
                 2014                                                2014                                2014

                 13.6%                                               617                                 207
                 2015                                                2015                                2015
                                                                                     Hours of Training
                                               Total Hours of Training               per Employee

                                               53,882                                12.4
                                               2014                                  2014

                                               96,123                                22.2
                                               2015                                  2015

                             Clinical Trials                                2014            2015

                             Number of Clinical Studies                     121             126
                                                                                                                          Environment                                             2014                          2015

                                                                                                                          Energy Consumption (GJ)                              493,097                        512,104
                             Number of Active Sites                         1,388           1,211

                                                                                                                          GHG Emissions (tons)                                  33,094                         34,221
                             Number of Patients in Clinical Trials          4,677           3,751
                                                                                                                          Water Consumption (cubic meters)                      74,317                        117,456

                                                                                                                          General Waste Produced (tons)                            460                          425
                             Research & Development                         2014            2015
                                                                                                                          Recycling (tons)                                       1,894                          422
                             Investment in R&D (mCHF)(6)                     97              89
                                                                                                                          Paper Consumption (tons)                               1,382                           93

                             Number of Employees in R&D                     421             450                           Investment in SHE (CHF)(7)                           927,000                        4,665,000
                                                                                                                          (Safety, Security, Health and Environment)

                             (6)
                                   Million Swiss francs                                                                   (7)
                                                                                                                                Investment figures in Swiss francs and also include the Diagnostics Division

26   Roche Latin America 2014-2015 Sustainability Report                                                                                                                          Roche Latin America 2014-2015 Sustainability Report   27
The region currently spends 7.6%
                                                                                         of its gross domestic product on
                                                                                         healthcare and this number is
                                                                                         expected to increase 4.6% every
                                                                                         year through 2018

                                                           Healthcare in Latin America
                                                           Latin America has experienced rapid and stable growth in recent
                                                           years, resulting in increased healthcare spending in and govern-
                                                           ment attention to programmes that improve access to healthcare.
                                                           The region currently spends 7.6% of its gross domestic product
                                                           on healthcare(8) and this number is expected to increase 4.6% ev-
                                                           ery year through 2018.(9) Despite these investments, significant
                                                           challenges remain, including a lack of infrastructure and trained
                                                           professionals, low levels of education and awareness, affordabil-
                                                           ity difficulties and disparities between local private and public
                                                           healthcare systems.

                                                           Countries in Latin America vary widely on a number of factors
                                                           that impact the healthcare landscape, including economic devel-
                                                           opment, social and cultural standards, regulatory approaches,
                                                           health infrastructure and perspectives on intellectual property.
                                                           Healthcare treatments also vary greatly between the private and
                                                           public healthcare sectors throughout Latin America. These dis-
                                                           crepancies can be found across healthcare expenditures, income
                                                           levels and levels of government funding in the region, and are
                                                           particularly impactful for complex diseases like cancer.

                                                           As a result, the cancer mortality rate in Latin America is higher
                                                           than that in the United States and Europe,(10) despite the region’s
                                                           lower incidence rate. To address this issue, many countries are
                                                           looking for new ways to sustainably increase access to healthcare.

                                                           (8)
                                                              The Economist Intelligence Unit. Healthcare 2015
                                                           (9)
                                                              Deloitte. 2015 Global Healthcare Outlook
                                                           (10)
                                                                Lancet Oncology 2013. Planning Cancer Control in Latin America and the Caribbean

28   Roche Latin America 2014-2015 Sustainability Report                                                        Roche Latin America 2014-2015 Sustainability Report   29
Roche in Latin America                                                   Roche has been a
                                                           Roche expanded to Latin America in 1930 with subsidiaries in             dedicated partner with
                                                           Buenos Aires, Argentina and Rio de Janeiro, Brazil. As of 2015,
                                                           Roche Latin America operates in 23 countries with regional               governments, physicians
                                                           headquarters in São Paulo, Brazil, and owns two manufacturing
                                                           plants in Mexico and Brazil.                                             and patient associations
                                                           Each country in Latin America faces unique healthcare challeng-          in Latin America for
                                                           es, and Roche’s commitment is as large and varied as the region
                                                           itself. Roche has been a dedicated partner with governments,             more than 80 years, and
                                                           physicians and patient associations in Latin America for more
                                                           than 80 years, and understands regional variations well. This            understands regional
                                                           experience helps us develop a nuanced approach based on local
                                                           market conditions.                                                       variations well.
                                                           Roche’s presence in Latin America is characterised by a deep
                                                           commitment to driving healthcare development and improve-
                                                           ment. In 2014 and 2015, more than 200,000 patients across Lat-
                                                           in America were treated with our strategic products in oncology
                                                           and immunology. We are also one of the three fastest growing
                                                           pharmaceutical companies. This growth is primarily driven by
                                                           the increasing availability and demand for biological therapies.
                                                           In the last two years, more than 50 Roche biological medica-
                                                           tions were approved in the region for a wide variety of diseases,
                                                           ranging from the treatment of cervical cancer to the treatment of
                                                           HER2-positive breast cancer. Roche embraces its responsibility as
                                                           a leader in oncology and understands the unique challenges Latin
                                                           America faces when it comes to cancer awareness, prevention,
                                                           diagnosis and treatment.

30   Roche Latin America 2014-2015 Sustainability Report                                                                       Roche Latin America 2014-2015 Sustainability Report   31
Sustainability Initiatives

                                                           Access to Healthcare

                                                           Roche Latin America believes that every person who needs our            to inadequacies in fundamental infrastructure, to political and
                                                           products should be able to access and benefit from them. For this       financial barriers. Roche takes a multi-stakeholder approach,
                                                           to happen, several conditions need to be in place, including disease    works to strengthen national cancer plans and partners within
                                                           awareness, adequate healthcare infrastructure and sufficient medi-      healthcare systems to increase access to tests and medicines.
                                                           cal coverage. Roche is committed to tailoring solutions on a coun-      Above all else, we work to elevate the patient voice to be sure our
                                                           try-by-country basis to fit each country’s unique needs.                most important stakeholders are heard. Through these activities,
                                                                                                                                   Roche supports the Group’s five primary pillars: Delivering In-
                                                           In Latin America, Roche works with a variety of partners across         novation, Increasing Disease Awareness, Strengthening Health-
                                                           issues and geographies to ensure we are effectively addressing          care Infrastructure, Improving Affordability and Supporting Lo-
                                                           problems ranging from lack of disease awareness or diagnostics,         cal Patient Organisations.

                                                           Delivering Innovation

                                                           As the population’s average age and life expectancy increase, de-       Research and Development:
                                                           mands on healthcare systems are growing exponentially. Health-          In Latin America, Roche is developing an innovation network of
                                                           care costs are rising and innovative medicines are expensive to         independent research and development centres. Roche invested
                                                           develop. At Roche we strive to provide our medicines to anyone          186 million CHF(11) in this network in 2014 and 2015, and has en-
                                                           who needs them, so we work closely with healthcare authorities          gaged 450 employees thus far. In addition to the results of the tri-
                                                           and other stakeholders to develop solutions to bring our medi-          als themselves, these efforts also benefit healthcare infrastructure
                                                           cines to more patients.                                                 and expand medical training, leading to higher quality patient
                                                                                                                                   treatment in participating hospitals.
                                                           To foster innovation, Roche partners with a diverse network of
                                                           organisations in Latin America and around the world. In 2014-           Clinical Trials:
                                                           2015 Roche Latin America was particularly focused on person-            Roche Latin America developed 121 clinical studies in 2014, en-
                                                           alised healthcare and biotechnology.                                    gaging 1,388 sites and 4,677 patients. In 2015 Roche developed
                                                                                                                                   126 studies across 1,211 sites that involved 3,751 patients.
                                                           Personalised Healthcare:
                                                           Roche is a global leader in personalised healthcare and is known        In 2014 our clinical studies produced great insight into combina-
                                                           for developing treatments that improve health standards and             tion therapies. In HER2-positive metastatic breast cancer, a par-
                                                           quality of life for patients. At present, approximately half of Roche   ticularly aggressive form of the disease, we found unprecedented
                                                           Latin America’s pharmaceutical projects are being developed in          data on one drug, which, when combined with chemotherapy and
                                                           parallel with diagnostic tests, leading to solutions that aim to fit    another treatment, increased survival time for patients to almost
                                                           the right treatment to the right patient.                               five years. Another study showed that when combining two drugs
                                                                                                                                   for advanced melanoma, the risk of the disease advancing was cut
                                                           Biotechnology:                                                          in half. Roche now has over 30 different combination therapies in
                                                           Biotechnology is fostering considerable advances in the treatment       its oncology pipeline.
                                                           of disease. Roche is currently the largest producer of medications
                                                           in the biotechnology industry, with the most sophisticated bio-         Since 2012 the U.S. Food and Drug Administration (FDA) has
                                                           pharmaceutical production unit in the world that is responsible         granted Breakthrough Therapy Designations to 12 indications of
                                                           for roughly 25% of global biological production capacity.               Roche medicines, four of them in 2015 alone.

                                                                                                                                   (11)
                                                                                                                                          Swiss francs

32   Roche Latin America 2014-2015 Sustainability Report                                                                                       Roche Latin America 2014-2015 Sustainability Report   33
Increasing Disease Awareness

                                                           At Roche, we recognize that raising awareness for health is just as
                                                           important to a patient’s well-being as proper diagnosis and treat-
                                                           ment. Greater public awareness of disease and symptoms can in-
                                                           crease prevention rates and help patients receive early, accurate
                                                           diagnoses. Throughout Latin America, we promoted and drove
                                                           awareness in 2014 and 2015 for a variety of diseases including
                                                           cancer, hepatitis, and cystic fibrosis, among others, across more
                                                           than 170 awareness campaigns.

                                                           Cancer Awareness:
                                                           To address high mortality rates for cancer across Latin America,
                                                           Roche offices throughout the region create and support various
                                                           awareness campaigns covering lymphoma, breast, ovarian, cer-
                                                           vical, colorectal, and lung cancers. These campaigns are devel-
                                                           oped to meet the unique needs of each country and they aim to
                                                           provide the public with proper information on prevention, early         Roche Press Day:
                                                           diagnosis and treatment options through websites, leaflets, con-        As journalists play a vital role in disseminating and deepening
                                                           ferences, forums, and the media. Beyond disseminating informa-          public knowledge to increase awareness, prevention, and ear-
                                                           tion, Roche also leads local activities that involve the community,     ly diagnosis of critical illnesses, we developed Roche Press Day
                                                           for example, local awareness walks to raise funds and awareness         (RPD) in 2012. The event is hosted annually and seeks to pro-
                                                           for a specific disease.                                                 mote knowledge exchange and continued education for many
                                                                                                                                   of today’s most serious diseases. Each year RPD brings togeth-
                                                           Breast cancer awareness month in October is an area of strong           er journalists from all over Latin America and expert panelists
                                                           support across Roche Latin America and in addition to the activ-        from around the world to discuss the latest scientific advances
                                                           ities mentioned, during the month some offices light their build-       and health-related issues and trends in the region. The event also
                                                           ing pink to recognise patients and Roche’s commitment to the            hosts the venue for recognizing the winners of the Roche Award
                                                           fight against the disease.                                              for Health Journalism. The award, organised by the Foundation
                                                                                                                                   for New Ibero-American Journalism (FNPI) and sponsored
                                                                                                                                   by Roche Latin America, honours and promotes high-quality
                                                                                                                                   health journalism.

                                                           Strengthening Healthcare Infrastructure                                         Roche works to develop
                                                           Latin America faces a variety of complex healthcare challenges,                 programmes that transfer
                                                           ranging from lack of basic infrastructure and education for health
                                                           professionals to gaps in public policy and healthcare regulation.               information and skills to
                                                           Roche aims to develop programmes that address these challenges
                                                           by driving efficiency in healthcare systems, promoting accessibil-              local partners.
                                                           ity and supporting infrastructure improvements.

                                                           We believe sustainable solutions that meet the needs of the
                                                           healthcare sector must go beyond traditional philanthropic mod-
                                                           els. Wherever possible, Roche works to develop programmes
                                                           that transfer information and skills to local partners. With this in    Diálogo Roche:
                                                           mind, we aim to provide benefits across the entire value chain and      This is the company’s official website for sharing scientific infor-
                                                           focus our efforts on initiatives that strengthen education, boost lo-   mation with healthcare professionals. It offers users relevant in-
                                                           cal infrastructure, support quality medicine production and dis-        formation on health issues, clinical studies, medical advances and
                                                           tribution and reinforce public policies. We know success requires       congresses, among others, to promote disease prevention. With
                                                           collaboration, and we work in partnership with key stakeholders         more than 46,000 registered physicians, the website is currently
                                                           including the medical and scientific communities, governmental          active in seven Latin American countries: Argentina, Brazil, Co-
                                                           agencies, research centres and healthcare professionals.                lombia, Mexico, Paraguay, Peru and Uruguay.

34   Roche Latin America 2014-2015 Sustainability Report                                                                                 Roche Latin America 2014-2015 Sustainability Report        35
Supporting Local Patient Organisations

                                                                                                                                                                                                             At Roche we recognise and support the great work being done
                                                                                                                                                                                                             by patient organisations to reduce barriers to healthcare and in-
                                                                                                                                                                                                             crease patient access. Here are a few examples of collaborative
                                                                                                                                                                                                             initiatives in this area:

                                                                                                                                                                                                             “Patient Voices in Action”:
                                                                                                                                                                                                             Roche launched “Patient Voices in Action” in 2013 to help pa-
                                                                                                                                                                                                             tient organisations improve their leadership, management and
                                                                                                                                                                                                             social action skills through an executive training programme in
                                                                                                                                                                                                             partnership with the Health and Aging Foundation of the Au-
                                                                                                                                                                                                             tonomous University of Barcelona. The first session was hosted
                                                                                                                                                                                                             in Panama in 2013 and followed by online learning modules
                                                                                                                                                                                                             throughout 2014, culminating in a final in-person meeting in
                                                                                                                                                                                                             Costa Rica during 2015.

                                                                                                                                                                                                             The introductory training session provided participating organ-
                                                                                                                                                                                                             isations with a step-by-step itinerary for learning and practicing
                                                                                                                                                                                                             social action skills. In the following e-learning opportunities, the
                                                                                                                                                                                                             programme offered a “meeting point” for participants to discuss
                                                                                                                                                                                                             needs and future challenges and share experiences, while also
                                                                                                                                                                                                             offering knowledge and tools to improve their daily practices.
                                                                                                                                                                                                             Through the course, participants could build their capacity to
                                                                                                                                                                                                             communicate with healthcare and social agents and use resources
                                                                                                                                                                                                             in a more effective way.

                                                                                                                                                                                                             A total of 36 patient organisations from 11 countries participated
                                                                                                                                                                                                             in the course, including: Argentina, Brazil, Chile, Colombia, Cos-
Improving Affordability                                                                                                                                                                                      ta Rica, Ecuador, Mexico, Panama, Peru, Uruguay and Venezuela.
                                                                                                                                                                                                             Many of the organisations are dedicated to oncological patients
Healthcare realities and challenges vary significantly across and     Patient Access in Latin America: Governance, Assessment              Organised by Roche Regional Market Access Latin America and       and other pathologies, including hepatitis and transplants.
within countries in Latin America. In recognition of these vari-      Methodologies, and Evidence-Informed Decision Making in              Global Health Policy teams in partnership with the Internation-
ables, Roche prioritises flexibility and tailors all programming to   Health Policy                                                        al Society For Pharmacoeconomics and Outcomes Research
adapt to each market. We focus on the specific barriers to access     Roche hosted a forum in 2015 that brought together 40 key stake-     (ISPOR), the conversation aimed to ensure that all participants
in each area, which can include a combination of socioeconomic        holders to discuss governance principles and methodologies for       involved have a good understanding of how evidence-informed
factors, disease epidemiology, political commitment, healthcare       reimbursement assessment decision-making in Latin America.           decision making can improve overall health system performance,
funding, health insurance coverage and the quality of healthcare      The participants included government officials, health technolo-     as well as the trade-offs in applying different approaches when
infrastructure. Roche works alongside government agencies at          gy assessment experts, patient group representatives, Roche rep-     assessing the value of healthcare technologies and services for
the national, state and municipal levels to support and promote       resentatives, and other key stakeholders (for example, therapeutic   specific interventions.
responsive healthcare systems that address the specific needs of      area experts, health economists and academics).
the population and reduce barriers to healthcare access.                                                                                   Following the event, Roche received 100% positive feedback from
                                                                                                                                           participants, who expressed interest in further engagement on
Roche’s approach to pricing also reflects the varying needs of each                                                                        this important topic. Two-thirds of respondents also mentioned
country in the Latin American region. Roche develops coun-                                                                                 that they view Roche as a credible voice on reimbursement as-
try-specific agreements that align with local needs, policies and                Roche prioritises                                         sessment methodologies in Latin America.
regulations. Currently we are piloting an assistance programme
to provide pharmaceuticals to the public healthcare system at                    flexibility and tailors                                   A follow-up webinar with participants, including stakeholders
lower prices than market rate. Initially this pilot has focused on                                                                         who could not participate in the forum due to other commit-
cancer, hepatitis C and other chronic disease treatments. Roche                  all programming to                                        ments, was scheduled for 2016 to ensure continued dialogue and
also provides direct assistance programmes to subsidise payment                                                                            strengthen relationships.
options for patients who are unable to afford health insurance.                  adapt to each market.

36         Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                     Roche Latin America 2014-2015 Sustainability Report        37
In 2015 Roche Latin
                                                                                                                                                                                   America provided a
                                                                                 Employees
                                                                                                                                                                                   total of 96,123 training
                                                                                 At Roche we believe success is driven by employees motivated
                                                                                 by a common purpose working in a culture of learning. Roche                                       hours, which translates
                                                                                 in Latin America is committed to creating a stimulating, partic-
                                                                                 ipatory work environment and creates initiatives to build the ca-                                 to 22.2 hours per
                                                                                 pacity, engagement, health and well-being of our employees. We
                                                                                 have invested in talent development, improved personnel man-                                      employee.
                                                                                 agement tools and policies, and offered training sessions on a va-
                                                                                 riety of topics. In 2015 Roche Latin America was ranked among
                                                                                 the best companies to work in the Great Place to Work® survey.

                                                                                 Roche Latin America currently employs 4,335 people, of whom
                                                                                 51% are women and 49% men. Among key leadership positions,
                                                                                 121 are filled by women, comprising 42% of total positions.
                                                                                                                                                            Diversity and Inclusion:
                                                                                 Roche Leadership is committed to seven principles: taking a genu-          Roche is committed to maintaining an environment where every-
                                                                                 ine interest in people; listening carefully, telling the truth, explain-   one contributes to our mission of delivering innovative diagnos-
                                                                                 ing ‘the why;’ empowering and trusting people to make decisions;           tics and developing life-saving treatments, regardless of gender,
                                                                                 discovering and developing the potential in people; striving for           race, ethnicity, sexual preference or religious background. Diver-
                                                                                 excellence and extraordinary results; setting priorities and simpli-       sity is a top priority for us, and we want to foster a workplace
                                                                                 fying work; and congratulating people for a job well done. Roche           where diversity goes beyond visible differences to encompass a
                                                                                 also provides resources and trainings for leadership development,          variety of educational backgrounds, professional knowledge,
                                                                                 as well as 360 degree feedback and performance management.                 personality types, thinking styles and life experiences. Emerg-
                                                                                 In 2015 Roche Latin America provided a total of 96,123 training            ing markets, like Latin America, are the most important growth
                                                                                 hours, which translates to 22.2 hours per employee.                        driver for Roche in the next 5-10 years. As a result, Roche ac-
                                                                                                                                                            tively works to foster diverse leadership that represents the global
                                                                                 Roche 2014 Global Employee Opinion Survey (GEOS):                          make-up of our portfolio and encourages best-practice sharing
                                                                                 Our 2014 GEOS received an 80% employee engagement rate and                 across markets. Integrating a variety of perspectives is crucial to
                                                                                 confirmed our talent management approach is on the right track.            developing new medicines and access programmes to address the
                                                                                 More than 80% of the employees surveyed said they would find it            needs of customers and patients in Latin America and beyond.
                                                                                 hard leaving the company and that they would recommend it to a
                                                                                 friend seeking employment.                                                 Live Well at Roche:
                                                                                                                                                            In 2013 Roche launched the global “Live well. Find your balance”
                                                                                 According to the survey, Roche Latin America’s employees value             programme, which includes a “Well-being week” for all employ-
                                                                                 the daily work and responsibilities given to each individual; the          ees. Hosted at more than 100 Roche locations worldwide, Roche
                                                                                 feeling of accomplishment and the impact of their work; and are            employees in all Latin American affiliates participated in Live
                                                                                 proud to work at Roche because of its reputation in the market.            Well events. Each location puts its own spin on the week, offering
                                                           In 2015 Roche Latin   The results of the survey were very positive, but we know we can           unique programmes that promote health, relaxation, nutrition
                                                                                 do even better. Each affiliate in Roche Latin America is working to        and exercise. Activities range from yoga classes to cooking work-
                                                           America was ranked    implement programmes for continuous improvement. We deeply                 shops, massages, birthday celebrations and football matches.
                                                                                 value our dialogue with employees and recognise it as an invalu-
                                                           among the best        able resource in our efforts to improve our business practices.

                                                           companies to work     In addition to our own employees, Roche is deeply committed to
                                                                                 ethical employment across the entire region and supports pro-
                                                           in the Great Place    grammes to fight child labour, forced labour and modern slave
                                                                                 labour practices in eight countries including Brazil, Nicaragua,
                                                           to Work® survey.      Honduras, Mexico, Guatemala, Dominican Republic, El Salvador
                                                                                 and Costa Rica.

38   Roche Latin America 2014-2015 Sustainability Report                                                                                                          Roche Latin America 2014-2015 Sustainability Report        39
Governance                                                                                                                                                                                                                  We take our responsibilities
Organisational Structure:                                            Ethics and Transparency:                                              The Roche Code of Conduct:                                                       seriously in order to meet
                                                                                                                                           The Roche Code of Conduct encompasses the Group’s Corporate
The Latin American Leadership Team (LLT) is responsible for          Roche’s primary objective is to meet patients’ and healthcare pro-    Principles, as well as the policies and references that guide the                high standards of business
corporate governance and management to ensure business sus-          fessionals’ needs for high-quality products and services. To meet     conduct of all staff members in all regions where the company
tainability in the short and long term, and is organised to foster   this objective, Roche must identify needs and problems in health-     operates. Employees are encouraged to seek guidance when in                      ethics and integrity.
innovation and collaboration in an open and transparent manner.      care and provide solutions. We take our responsibilities seriously    doubt about the correct way to proceed in business, and to re-
This culture allows Roche to learn from both success and failure     in order to meet high standards of business ethics and integri-       port cases of possible issues involving compliance and ethics. The
and set meaningful goals for the future.                             ty. This is instrumental to our sustainable success, and hence to     code also addresses situations of conflict of interest that must be
                                                                     our ability to make a lasting impact on public health. Integrity at   reported by executives. To help employees, the company has a
                                                                     Roche means doing things right from the start.                        speak-up line to report potential compliance violations.
     Executive Committees: Each country within Roche Latin
     America has an Executive Committee, comprised of the            Our commitment includes full respect for patients’ individual         Supplier Engagement Programme:
     country president, executives, and managers, that reports       rights. We also build respect for the individual into all our work    Roche’s goal is to be one of the top three companies in sustain-      In Latin America we have conducted 140 supplier audits in the
     to the regional Head. The purpose of this committee is to       and for all members of the organisation, and apply our Corporate      ability in the health industry. To achieve this, Roche needs a sup-   last two years to ensure compliance with Roche and industry
     ensure responsible management and organisational align-         Principles in our relations with business partners. We are com-       ply chain that supports and implements these same principles.         codes and standards. All of our suppliers also receive training on
     ment between each country affiliate and the Group. In cer-      mitted to maintaining high ethical and social standards in our        To this end, the company has maintained a Code of Conduct for         our Code of Conduct and have to accept it in order to be one of
     tain countries, such as Brazil, Roche also has Compliance       business dealings, in our approach to medical science, and in our     Suppliers since 2010 and expects every company or profession-         our business partners. Suppliers who exceed expectations are also
     and Sustainability Committees, which specifically address       efforts to protect the environment and ensure good citizenship.       al maintaining commercial relations with Roche to comply with         recognized by Roche Latin America for their outstanding service
     relevant issues in the country.                                 We are committed to innovation and benchmarking our prin-             this Code of Conduct. The Code provides guidance for suppliers        as encouragement for all suppliers to perform their best.
                                                                     ciples and achievements against the industry and best practice,       on issues relating to sustainability with emphasis on its impor-
                                                                     which includes transparent reporting.                                 tance to Roche. Through the Code, the company requires its sup-
                                                                                                                                           pliers to adhere to specific sustainability principles: ethics, em-
                                                                                                                                           ployment, health and safety, environment, management systems,
                                                                                                                                           innovation, economic sustainability, and diversity of suppliers.

40           Roche Latin America 2014-2015 Sustainability Report                                                                                                                                                       Roche Latin America 2014-2015 Sustainability Report      41
You can also read